Published in Curr Treatm Opt Rheumatol on March 01, 2015
A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology (2013) 8.37
Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol (2013) 6.82
Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med (2004) 6.21
Clinical guideline: management of gastroparesis. Am J Gastroenterol (2012) 3.86
Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation (2013) 3.45
Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2013) 3.43
Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol (2004) 3.15
Gastric antral vascular ectasia: the watermelon stomach. Gastroenterology (1984) 3.03
Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil (2006) 2.61
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. Gastrointest Endosc (2008) 2.37
Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med (1991) 2.32
Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med (2008) 2.22
Gastrointestinal motility disorders in scleroderma. Arthritis Rheum (1994) 2.04
Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind study. Aliment Pharmacol Ther (2014) 1.99
Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2012) 1.96
Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology (2006) 1.87
Esophageal dilation. Gastrointest Endosc (2006) 1.68
Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther (2007) 1.67
The watermelon stomach: long-term outcome in patients treated with Nd:YAG laser therapy. Gastrointest Endosc (1995) 1.63
A review of endoscopic methods of esophageal dilation. J Clin Gastroenterol (2002) 1.62
Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut (2014) 1.54
Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion (2008) 1.52
The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med (1993) 1.50
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut (2005) 1.49
Endoscopy in eosinophilic esophagitis: "feline" esophagus and perforation risk. Clin Gastroenterol Hepatol (2003) 1.46
Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol (1997) 1.45
Cardiac arrest after labetalol and metoclopramide administration in a patient with scleroderma. Anesth Analg (2002) 1.42
Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. Am J Gastroenterol (2006) 1.41
Clinical images: Gastric antral vascular ectasia in systemic sclerosis. Arthritis Rheum (2010) 1.40
Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum (2009) 1.37
Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther (2005) 1.34
Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol (1996) 1.34
American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology (2004) 1.30
Endoscopic laser therapy for watermelon stomach. Gastroenterology (1989) 1.29
Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology (2006) 1.28
Review article: current therapeutic options for gastric antral vascular ectasia. Aliment Pharmacol Ther (2003) 1.22
Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum (2008) 1.21
Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther (1999) 1.20
Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum (2007) 1.20
Prokinetics in patients with gastroparesis: a systematic analysis. Digestion (1999) 1.16
In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res (2009) 1.16
Gastroparesis: current diagnostic challenges and management considerations. World J Gastroenterol (2009) 1.16
Antireflux operations in patients with scleroderma. Ann Thorac Surg (1994) 1.14
Comparison of surgical approaches to recalcitrant gastroesophageal reflux disease in the patient with scleroderma. Ann Thorac Surg (2007) 1.13
Esophageal disease in scleroderma. J Clin Gastroenterol (2006) 1.12
Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther (2006) 1.11
Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol (2014) 1.10
Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis (2010) 1.09
Patient-reported outcomes in gastroenterology: clinical and research applications. J Neurogastroenterol Motil (2013) 1.07
Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility. Scand J Gastroenterol (2009) 1.07
Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes (2014) 1.06
Argon plasma coagulation, bipolar cautery, and cryotherapy: ABC's of ablative techniques. Endoscopy (2008) 1.05
Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum (1994) 1.02
The management of portal hypertensive gastropathy and gastric antral vascular ectasia. Dig Liver Dis (2010) 1.02
Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep (2012) 1.01
Endoscopic cryotherapy for the management of gastric antral vascular ectasia. Gastrointest Endosc (2008) 1.00
Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) (2010) 0.99
Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol (2008) 0.99
Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol (2008) 0.99
Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum (2005) 0.98
Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance. Curr Cardiol Rev (2009) 0.98
Endoscopic band ligation versus argon plasma coagulation for gastric antral vascular ectasia associated with liver diseases. Dig Endosc (2011) 0.98
Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheum (1996) 0.98
Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum (2010) 0.97
Pneumatosis cystoides intestinalis in scleroderma-related conditions. Intern Med J (2012) 0.97
Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. Clin Gastroenterol Hepatol (2013) 0.96
Assessment of gastrointestinal involvement. Clin Exp Rheumatol (2003) 0.96
Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol (2014) 0.96
Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) (2009) 0.95
Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int (2010) 0.94
Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum (2001) 0.94
Gastric and enteric involvement in progressive systemic sclerosis. J Clin Gastroenterol (2008) 0.93
Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center's experience. J Clin Gastroenterol (1999) 0.93
Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci (1995) 0.93
Patient perception of UK scleroderma services--results of an anonymous questionnaire. Rheumatology (Oxford) (2006) 0.92
[Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study]. Acta Gastroenterol Latinoam (2010) 0.92
Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus (2005) 0.92
Systemic sclerosis--challenges for clinical practice. Nat Rev Rheumatol (2012) 0.92
Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol (2010) 0.91
Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford) (2013) 0.90
Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther (2008) 0.90
Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol (2007) 0.90
Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci (2007) 0.90
Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth. Aliment Pharmacol Ther (2010) 0.90
Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut (2002) 0.89
Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. Transplant Proc (2010) 0.89
Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis. J Rheumatol (2012) 0.88
The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers. Aliment Pharmacol Ther (2003) 0.87
Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol (2014) 0.87
Argon photocoagulation in the treatment of gastric antral vascular ectasia and radiation proctitis. Can J Gastroenterol (2009) 0.87
Gastric antral vascular ectasia: case report and review of the literature. Clin Med Res (2012) 0.86
Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. Dis Esophagus (2010) 0.85
Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am (1998) 0.85
Diabetic gastropathy and prokinetics. Am J Gastroenterol (2003) 0.85
Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol (2013) 0.85
Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction. J Rheumatol (2014) 0.84
Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis (1992) 0.84
Quality of life and morbidity after permanent sacral nerve stimulation for fecal incontinence. Arch Surg (2007) 0.84
Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. J Rheumatol (2009) 0.84